

Richard A Scolyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6697919/publications.pdf>

Version: 2024-02-01

801
papers

68,520
citations

993

114
h-index

1185

228
g-index

833
all docs

833
docs citations

833
times ranked

62540
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. <i>Experimental Dermatology</i> , 2022, 31, 13-30.	1.4	14
2	Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. <i>Pathology</i> , 2022, 54, 369-371.	0.3	2
3	Residual melanoma in wide local excision specimens after "complete"™ excision of primary cutaneous in situ and invasive melanomas. <i>Pathology</i> , 2022, 54, 71-78.	0.3	2
4	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1607-1616.	0.3	11
5	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF). <i>JAMA Dermatology</i> , 2022, 158, 33.	2.0	26
6	Pathology: the next chapter. <i>Pathology</i> , 2022, 54, 4-5.	0.3	1
7	Successful treatment of eruptive keratoacanthomas with actitrein for patients on checkpoint inhibitor immunotherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
8	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
9	Dermoscopic features and screening strategies for the detection of small-diameter melanomas. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 932-941.	0.6	11
10	Do we need to rethink the diagnoses melanoma <i>in situ</i> and severely dysplastic naevus?. <i>British Journal of Dermatology</i> , 2022, 186, 1030-1032.	1.4	12
11	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	7.7	64
12	Competing risks analysis with missing cause-of-failure" penalized likelihood estimation of cause-specific Cox models. <i>Statistical Methods in Medical Research</i> , 2022, , 096228022110702.	0.7	0
13	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15mm in thickness). <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 298-305.	0.6	3
14	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
15	Re: Reply to letter to the editor re: "practical guide on the use of imiquimod cream to treat lentigo maligna"™. <i>Australasian Journal of Dermatology</i> , 2022, , .	0.4	0
16	Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1843-e1849.	1.8	22
17	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. <i>JAMA Surgery</i> , 2022, 157, 335.	2.2	20
18	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>European Journal of Surgical Oncology</i> , 2022, 48, 1280-1287.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	0.8	43
20	The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. <i>Lung Cancer</i> , 2022, 165, 124-132.	0.9	15
21	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.4	1
22	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. <i>European Journal of Cancer</i> , 2022, 167, 133-141.	1.3	3
23	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. <i>Medical Journal of Australia</i> , 2022, 217, 208-209.	0.8	3
24	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. <i>Pathology</i> , 2022, , .	0.3	1
25	Reflectance confocal microscopy – a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
26	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. <i>European Journal of Cancer</i> , 2022, 167, 123-132.	1.3	4
27	Anatomic position determines oncogenic specificity in melanoma. <i>Nature</i> , 2022, 604, 354-361.	13.7	44
28	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. <i>Pathology</i> , 2022, 54, 533-540.	0.3	3
29	Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. <i>Dermatologic Therapy</i> , 2022, , e15472.	0.8	1
30	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
31	Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
32	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	1.3	2
33	Effect of the SunSafe Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. <i>Clinical and Experimental Dermatology</i> , 2022, , .	0.6	0
34	Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevii. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1048-1059.	2.1	3
35	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. <i>Australasian Journal of Dermatology</i> , 2022, , .	0.4	2
36	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5937-5945.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	0.6	0
38	Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	9
39	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	15.2	121
40	Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridgeâ€”December 1stâ€”2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	3
41	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
42	Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9580-9580.	0.8	1
43	The Association Between Excision Margins and Local Recurrence in 1407 Patients with Primary In Situ Melanomas. <i>JAAD International</i> , 2022, , .	1.1	2
44	Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9572-9572.	0.8	8
45	A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21556-e21556.	0.8	0
46	Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 7019-7028.	0.7	3
47	VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: Meta-analysis and systematic review.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3024-3024.	0.8	0
48	NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9503-9503.	0.8	16
49	The interferon-gamma (IFN- γ) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9539-9539.	0.8	8
50	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9605-TPS9605.	0.8	19
51	A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9599-TPS9599.	0.8	0
52	Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine. <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	3
53	Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. <i>EBioMedicine</i> , 2022, 82, 104143.	2.7	12
54	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. <i>British Journal of Cancer</i> , 2021, 124, 156-160.	2.9	21

#	ARTICLE	IF	CITATIONS
55	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1145-1151.	0.5	5
56	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. <i>British Journal of Surgery</i> , 2021, 108, 550-553.	0.1	7
57	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. <i>Australasian Journal of Dermatology</i> , 2021, 62, 168-176.	0.4	3
58	GLI activated epithelioid cell tumour: report of a case and proposed new terminology. <i>Pathology</i> , 2021, 53, 267-270.	0.3	9
59	The tumour immune landscape and its implications in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 529-549.	1.5	21
60	Targeting the Microbiome to Overcome Resistance. <i>Cancer Cell</i> , 2021, 39, 151-153.	7.7	6
61	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , 2021, 53, 141-156.	0.3	126
62	C9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 2624-2635.	3.2	22
63	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 166.	2.0	21
64	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	15.2	218
65	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263.	15.2	190
66	Î³Î´ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021, 9, 612-623.	1.6	22
67	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021, 12, 1434.	5.8	46
68	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. <i>Cancers</i> , 2021, 13, 1363.	1.7	24
69	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1290-1298.	1.3	14
70	Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1315-1322.	1.3	16
71	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021, 32, 375-383.	0.6	25
72	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3704-e3713.	1.8	98

#	ARTICLE	IF	CITATIONS
73	Estimating the potential impact of interventions to reduce overcalling and undercalling of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1519-1527.	1.3	3
74	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. <i>Journal of Clinical Oncology</i> , 2021, 39, 1243-1252.	0.8	28
75	A multicentre study of naevus-associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. <i>British Journal of Dermatology</i> , 2021, 185, 101-109.	1.4	13
76	Publication metrics: it really is all about the numbers. <i>Pathology</i> , 2021, 53, 561-563.	0.3	2
77	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. <i>Cancers</i> , 2021, 13, 1740.	1.7	17
78	Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9508-9508.	0.8	41
79	Predicting sentinel node positivity in patients with melanoma: external validation of a risk prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort*. <i>British Journal of Dermatology</i> , 2021, 185, 412-418.	1.4	14
80	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. <i>Trials</i> , 2021, 22, 324.	0.7	10
81	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , 2021, 13, 81.	3.6	25
82	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. <i>European Journal of Cancer</i> , 2021, 148, 51-57.	1.3	16
83	Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations. <i>Advances in Therapy</i> , 2021, 38, 3506-3530.	1.3	9
84	Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2021, 5, A876-A877.	0.1	1
85	The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	23
86	Neoadjuvant immunotherapy in melanoma - the new frontier. <i>Clinical Cancer Research</i> , 2021, 27, clincanres.1236.2021.	3.2	2
87	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 672521.	2.2	13
88	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/ Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	1.7	11
89	Counting mitoses: SI(ze) matters!. <i>Modern Pathology</i> , 2021, 34, 1651-1657.	2.9	61
90	Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi. <i>JAMA Dermatology</i> , 2021, 157, 836-841.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Mucosal Melanoma. <i>Surgical Pathology Clinics</i> , 2021, 14, 293-307.	0.7	1
92	Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1811-1820.	1.3	3
93	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. <i>Pathology</i> , 2021, 53, 830-835.	0.3	7
94	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	0.6	22
95	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1597-1605.	2.1	16
96	Histological regression in melanoma: impact on sentinel lymph node status and survival. <i>Modern Pathology</i> , 2021, 34, 1999-2008.	2.9	16
97	Analysis of clinical and molecular profiles of patients with innate resistance to ANTI-PD-1 +/- ANTI-CTLA-4 immunotherapy in metastatic melanoma. <i>Pathology</i> , 2021, 53, S60.	0.3	0
98	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 700-710.	1.4	12
99	Abstract 2609: Hypoxia-mediated downregulation of GCNT2/l-antigen in metastatic melanoma accelerates disease progression and mortality. , 2021, , .		0
100	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. <i>Nature Cancer</i> , 2021, 2, 693-708.	5.7	102
101	Abstract 2762: Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets). , 2021, , .		0
102	Abstract 2761: CODEX highly multiplex image mapping to CITEseq datasets reveal the spatial dynamics of the TME during the development of acquired resistant in immunotherapy treated melanoma. , 2021, , .		1
103	ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control. <i>Annals of Surgical Oncology</i> , 2021, 28, 6124-6125.	0.7	0
104	Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ. <i>International Journal of Dermatology</i> , 2021, 61, 167.	0.5	5
105	Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Appliedâ€”Reply. <i>JAMA Dermatology</i> , 2021, 157, 1006.	2.0	0
106	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	1.3	1
107	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	0.7	8
108	ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 597-598.	0.7	1

#	ARTICLE	IF	CITATIONS
109	1092TiP Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02. <i>Annals of Oncology</i> , 2021, 32, S903.	0.6	0
110	A practical guide on the use of imiquimod cream to treat lentigo maligna. <i>Australasian Journal of Dermatology</i> , 2021, 62, 478-485.	0.4	4
111	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10568.	1.8	0
112	1500P Health-related quality of life in melanoma patients treated with neoadjuvant nivolumab and domatinostat: Preliminary results. <i>Annals of Oncology</i> , 2021, 32, S1100-S1101.	0.6	0
113	LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN- γ sign): The DONIMI study. <i>Annals of Oncology</i> , 2021, 32, S1315.	0.6	4
114	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. <i>Annals of Oncology</i> , 2021, 32, S1314-S1315.	0.6	21
115	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021, 12, 1137.	5.8	33
116	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
117	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
118	Association Between Melanoma Detected During Routine Skin Checks and Mortality. <i>JAMA Dermatology</i> , 2021, 157, 1425.	2.0	27
119	Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children. <i>Pediatric Dermatology</i> , 2021, , .	0.5	0
120	Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. <i>Human Molecular Genetics</i> , 2021, 29, 3578-3587.	1.4	3
121	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolmmunology</i> , 2020, 9, 1659093.	2.1	62
122	Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna. <i>Dermatology</i> , 2020, 236, 111-116.	0.9	23
123	From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. <i>Human Pathology</i> , 2020, 95, 149-160.	1.1	6
124	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 910-919.	0.6	10
125	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 357-367.	2.1	10
126	Melanoma pathology reporting and staging. <i>Modern Pathology</i> , 2020, 33, 15-24.	2.9	61

#	ARTICLE	IF	CITATIONS
127	Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. <i>Melanoma Research</i> , 2020, 30, 193-197.	0.6	32
128	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	1.1	59
129	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259.	5.8	102
130	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	6.6	79
131	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579.	0.6	18
132	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	3.2	41
133	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
134	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	1.7	27
135	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
136	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020, 126, 4717-4725.	2.0	14
137	Prognostic Gene Expression Profiling in Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 1004.	2.0	59
138	Multiplex melanoma families are enriched for polygenic risk. <i>Human Molecular Genetics</i> , 2020, 29, 2976-2985.	1.4	9
139	Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 335-352.	1.1	20
140	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	1.7	22
141	P01.15...Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature " the DONIMI study. , 2020, , .		1
142	L3...Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients. , 2020, 8, A2.1-A2.		2
143	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020, 8, 1346-1353.	1.6	13
144	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22

#	ARTICLE	IF	CITATIONS
145	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. <i>JCO Precision Oncology</i> , 2020, 4, 990-991.	1.5	2
146	Publication metrics: what do they mean?. <i>Pathology</i> , 2020, 52, 619-620.	0.3	5
147	Primary dermal melanoma: clinical behaviour, prognosis and treatment. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2131-2139.	0.5	5
148	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. <i>Nature Communications</i> , 2020, 11, 2408.	5.8	86
149	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 2719-2727.	0.8	84
150	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 757.	1.3	11
151	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 372.	2.2	20
152	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. <i>BMJ Open</i> , 2020, 10, e032636.	0.8	6
153	Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2317-e2318.	1.8	0
154	Temporal and spatial modulation of the tumor and systemic immune response in the murine G1261 glioma model. <i>PLoS ONE</i> , 2020, 15, e0226444.	1.1	16
155	The prognostic significance of microsatellites in cutaneous melanoma. <i>Modern Pathology</i> , 2020, 33, 1369-1379.	2.9	13
156	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 500-522.	1.2	239
157	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020, 1, 197-209.	5.7	30
158	Staging for Melanoma - Toward a New Paradigm?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 873-874.	3.0	2
159	Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 171-179.	1.6	24
160	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23
161	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
162	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 4064-4071.	3.2	50

#	ARTICLE	IF	CITATIONS
163	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	9.4	138
164	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 195-206.	1.3	35
165	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. <i>Nature Communications</i> , 2020, 11, 1897.	5.8	165
166	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
167	Classification and Histopathology of Melanoma. , 2020, , 317-379.		1
168	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials. <i>Cancer Research</i> , 2020, 80, 3412-3412.	0.4	8
169	Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy. , 2020, , .		6
170	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10015-10015.	0.8	18
171	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10087-TPS10087.	0.8	9
172	Australian general practitionersâ€™ attitudes and knowledge of sentinel lymph node biopsy in melanoma management. <i>Australian Journal of General Practice</i> , 2020, 49, 355-362.	0.3	3
173	A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10088-TPS10088.	0.8	2
174	Abstract 3271: Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial. <i>Cancer Research</i> , 2020, 80, 3271-3271.	0.4	1
175	Abstract 913: Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy. <i>Cancer Research</i> , 2020, 80, 913-913.	0.4	1
176	Melanoma Prognosis and Staging. , 2020, , 271-297.		2
177	426â€™...MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. , 2020, , .		0
178	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 38-47.	0.7	11
179	Desmoplastic Melanoma. , 2019, , 469-481.		0
180	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. <i>Trials</i> , 2019, 20, 477.	0.7	4

#	ARTICLE	IF	CITATIONS
181	Diagnosing melanoma: the method matters. <i>Medical Journal of Australia</i> , 2019, 211, 209-210.	0.8	1
182	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	5.8	205
183	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. <i>British Journal of Surgery</i> , 2019, 106, 1319-1326.	0.1	5
184	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
185	Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5499-5506.	1.8	85
186	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. <i>Journal of Surgical Oncology</i> , 2019, 120, 1462-1469.	0.8	6
187	Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S139-S140.	0.4	0
188	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. <i>Annals of Surgical Oncology</i> , 2019, 26, 4663-4672.	0.7	3
189	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3141.	0.8	78
190	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	5.1	346
191	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	5.1	126
192	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019, 10, 2230.	5.8	21
193	Molecular Genomic Profiling of Melanocytic Nevus. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1762-1768.	0.3	55
194	Pathological re-classification of basal cell carcinomas from the ontrac skin cancer chemoprevention study and the new who skin blue book. <i>Pathology</i> , 2019, 51, S8.	0.3	0
195	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019, 7, 559-571.	1.6	79
196	Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. <i>European Journal of Cancer</i> , 2019, 112, 9-11.	1.3	6
197	Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. <i>Oral Oncology</i> , 2019, 92, 33-39.	0.8	43
198	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	0.6	77

#	ARTICLE	IF	CITATIONS
199	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1314-1322.	3.0	35
200	Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis. <i>European Journal of Cancer</i> , 2019, 110, S21-S22.	1.3	0
201	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	7.7	547
202	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 3247-3258.	3.2	27
203	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. <i>JAMA Dermatology</i> , 2019, 155, 502.	2.0	0
204	18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. <i>Annals of Oncology</i> , 2019, 30, v910.	0.6	16
205	Novel Immune Targets in Melanoma Response. <i>Clinical Cancer Research</i> , 2019, 25, 5424-5425.	3.2	1
206	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	1.7	14
207	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 2041.	1.7	17
208	IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2019, 21, vi119-vi119.	0.6	0
209	Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1442-1444.	2.1	4
210	Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 5074.	1.3	6
211	Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma"; <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e21-e22.	0.6	1
212	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019, 144, 1049-1060.	2.3	54
213	bcGST: an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. <i>Bioinformatics</i> , 2019, 35, 1350-1357.	1.8	1
214	Metastatic Melanoma. , 2019, , 314-329.		1
215	RAB27A promotes melanoma cell invasion and metastasis via regulation of proinvasive exosomes. <i>International Journal of Cancer</i> , 2019, 144, 3070-3085.	2.3	72
216	Combined Melanocytic Nevi. , 2019, , 112-123.		0

#	ARTICLE	IF	CITATIONS
217	Acral and Subungual Melanoma. , 2019, , 168-180.		0
218	Prognosis, Staging, and Reporting of Melanomas. , 2019, , 386-396.		4
219	Tissue-resident memory CD8+ T cells promote melanoma immune equilibrium in skin. <i>Nature</i> , 2019, 565, 366-371.	13.7	266
220	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828.	1.6	16
221	Subungual Melanoma of the Hand. <i>Annals of Surgical Oncology</i> , 2019, 26, 1035-1043.	0.7	28
222	A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. <i>Journal of Investigative Dermatology</i> , 2019, 139, 467-469.	0.3	17
223	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1 Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	3.2	249
224	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	3.2	57
225	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. <i>Annals of Surgical Oncology</i> , 2019, 26, 25-32.	0.7	21
226	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Onc Immunology</i> , 2019, 8, e1537581.	2.1	61
227	The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population based data on diagnosis and management. <i>Australasian Journal of Dermatology</i> , 2019, 60, 118-125.	0.4	21
228	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. <i>Pathology</i> , 2019, 51, 39-45.	0.3	25
229	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. <i>Australasian Journal of Dermatology</i> , 2019, 60, 75-76.	0.4	1
230	Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma. , 2019, , .		2
231	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9500-9500.	0.8	3
232	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9503-9503.	0.8	34
233	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9511-9511.	0.8	3
234	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9596-TPS9596.	0.8	5

#	ARTICLE	IF	CITATIONS
235	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	0.8	16
236	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	0.8	31
237	Management of pigmented skin lesions in childhood and adolescence. Australian Journal of General Practice, 2019, 48, 539-544.	0.3	5
238	Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. Australian Journal of General Practice, 2019, 48, 357-362.	0.3	9
239	Classification and Histopathology of Melanoma. , 2019, , 1-64.		0
240	Desmoplastic Melanoma. , 2019, , 1-13.		0
241	Melanoma Prognosis and Staging. , 2019, , 1-27.		0
242	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. Journal of Clinical Oncology, 2019, 37, TPS145-TPS145.	0.8	1
243	Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).. Journal of Clinical Oncology, 2019, 37, 9581-9581.	0.8	2
244	Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).. Journal of Clinical Oncology, 2019, 37, 9542-9542.	0.8	2
245	Management of pigmented skin lesions during pregnancy. Australian Journal of General Practice, 2019, 48, 621-624.	0.3	5
246	Abstract 2822: Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy. , 2019, , .		2
247	Abstract 3246: Dynamics of T-cell checkpoint receptor profiles during melanoma progression. , 2019, , .		0
248	Pigmented Paget's disease of the nipple mistaken for melanoma in situ : a diagnostic pitfall for the unwary. Pathology, 2018, 50, 364-367.	0.3	3
249	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
250	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	13.5	1,670
251	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	13.5	1,718
252	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	13.5	228

#	ARTICLE	IF	CITATIONS
253	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	13.5	272
254	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
255	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	13.5	2,111
256	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018, 173, 355-370.e14.	13.5	620
257	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018, 23, 282-296.e4.	2.9	333
258	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	2.9	407
259	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	2.9	245
260	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018, 23, 297-312.e12.	2.9	205
261	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
262	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018, 23, 181-193.e7.	2.9	683
263	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	6.6	3,706
264	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 172-180.e3.	2.9	119
265	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018, 23, 213-226.e3.	2.9	83
266	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 239-254.e6.	2.9	801
267	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018, 23, 255-269.e4.	2.9	204
268	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018, 23, 270-281.e3.	2.9	177
269	Germline BAP1 -positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. <i>European Journal of Cancer</i> , 2018, 92, 48-53.	1.3	29
270	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3

#	ARTICLE	IF	CITATIONS
271	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	3.4	229
272	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. <i>American Journal of Surgical Pathology</i> , 2018, 42, 359-366.	2.1	11
273	RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. <i>Scientific Reports</i> , 2018, 8, 653.	1.6	13
274	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8mm Separates Higher-Risk and Lower-Risk Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 894-902.	0.7	69
275	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	13.7	269
276	Telomere sequence content can be used to determine ALT activity in tumours. <i>Nucleic Acids Research</i> , 2018, 46, 4903-4918.	6.5	40
277	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	3.2	297
278	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018, 6, 271-281.e7.	2.9	605
279	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018, 6, 282-300.e2.	2.9	284
280	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018, 33, 706-720.e9.	7.7	400
281	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	7.7	750
282	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	7.7	396
283	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	7.7	478
284	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	5.1	732
285	A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700094.	0.8	0
286	The Importance of Population-Based Estimates of Melanocytic Pathology. <i>JAMA Dermatology</i> , 2018, 154, 15.	2.0	1
287	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289
288	Trajectories of premalignancy during the journey from melanocyte to melanoma. <i>Pathology</i> , 2018, 50, 16-23.	0.3	23

#	ARTICLE	IF	CITATIONS
289	Punch â€“scoringâ€™: a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions. <i>Histopathology</i> , 2018, 72, 294-304.	1.6	5
290	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). <i>Annals of Oncology</i> , 2018, 29, viii734.	0.6	9
291	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2018, 25, 918-919.	0.7	1
292	Epigenetic profiling for the molecular classification of metastatic brain tumors. <i>Nature Communications</i> , 2018, 9, 4627.	5.8	79
293	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	2.9	134
294	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , 2018, 25, 1304-1317.e5.	2.9	329
295	Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. <i>Pathology</i> , 2018, 50, 648-653.	0.3	8
296	Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. <i>Journal of Surgical Oncology</i> , 2018, 118, 599-605.	0.8	13
297	Staging of Cutaneous Melanoma. <i>JAMA Network Open</i> , 2018, 1, e180086.	2.8	4
298	Melanoma protective antitumor immunity activated by catalytic DNA. <i>Oncogene</i> , 2018, 37, 5115-5126.	2.6	15
299	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	0.6	135
300	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018, 34, 211-224.e6.	7.7	623
301	SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. <i>Nature Communications</i> , 2018, 9, 3440.	5.8	80
302	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. <i>British Journal of Cancer</i> , 2018, 119, 713-723.	2.9	9
303	Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. <i>Annals of Surgical Oncology</i> , 2018, 25, 2105-2110.	0.7	338
304	History of Melanoma. , 2018, , 1-13.		1
305	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. <i>Clinical Cancer Research</i> , 2018, 24, 4494-4504.	3.2	28
306	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 584.	1.3	14

#	ARTICLE	IF	CITATIONS
307	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. <i>Scientific Data</i> , 2018, 5, 180245.	2.4	18
308	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9604-TPS9604.	0.8	8
309	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9606-TPS9606.	0.8	8
310	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9518-9518.	0.8	0
311	Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing. , 2018, , .		0
312	Abstract LB-146: T cell receptor immunosequencing improves prediction of melanoma recurrence. , 2018, , .		0
313	Abstract 2420: Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress. , 2018, , .		0
314	Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 1378-1385.	0.7	17
315	SF3B1 and BAP1 mutations in blue nevus-like melanoma. <i>Modern Pathology</i> , 2017, 30, 928-939.	2.9	81
316	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. <i>Laboratory Investigation</i> , 2017, 97, 130-145.	1.7	40
317	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	3.2	192
318	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	13.7	1,068
319	The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1. <i>Clinical Cancer Research</i> , 2017, 23, 2921-2923.	3.2	5
320	Authors' response to a reply to "A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients"™. <i>British Journal of Dermatology</i> , 2017, 176, 552-553.	1.4	2
321	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017, 52, 71-81.	3.4	437
322	Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2033-2035.	0.3	24
323	Computer-assisted diagnosis for skin cancer: have we been outsmarted?. <i>Lancet, The</i> , 2017, 389, 1962-1964.	6.3	11
324	Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2016-2024.	1.3	19

#	ARTICLE	IF	CITATIONS
325	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. <i>Annals of Oncology</i> , 2017, 28, 1130-1136.	0.6	253
326	5â€Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 249-255.	0.7	14
327	Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. <i>Modern Pathology</i> , 2017, 30, 350-356.	2.9	56
328	Mutation load in melanoma is affected by <i><sc>MC</sc>1R</i> genotype. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 255-258.	1.5	19
329	Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress. <i>Cancer Research</i> , 2017, 77, 6226-6239.	0.4	43
330	Melanoma staging: Evidenceâ€based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
331	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	6.6	207
332	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	5.8	109
333	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	3.2	75
334	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. <i>Modern Pathology</i> , 2017, 30, 1538-1550.	2.9	33
335	Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. <i>European Journal of Cancer</i> , 2017, 82, 167-170.	1.3	11
336	(S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E9.	0.4	0
337	Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma. <i>Pathology</i> , 2017, 49, 539-542.	0.3	11
338	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	2.9	150
339	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<math>\leq 0.1\text{mm}</math>) Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 660-660.	0.7	1
340	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleuralâ€Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1421-1433.	0.5	121
341	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.4	126
342	Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia. <i>Annals of Surgical Oncology</i> , 2017, 24, 2080-2088.	0.7	31

#	ARTICLE	IF	CITATIONS
343	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
344	Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. <i>Biomarker Research</i> , 2017, 5, 17.	2.8	11
345	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. <i>Laboratory Investigation</i> , 2017, 97, 176-186.	1.7	14
346	InÂvivo reflectance confocal microscopy for evaluating melanoma of the lip and its differential diagnoses. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 123, 84-94.	0.2	12
347	Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. <i>British Journal of Dermatology</i> , 2017, 177, 574-577.	1.4	8
348	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma. <i>Annals of Oncology</i> , 2017, 28, v432.	0.6	30
349	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	8
350	Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. <i>Melanoma Management</i> , 2017, 4, 147-149.	0.1	1
351	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. <i>Biomarker Research</i> , 2017, 5, 32.	2.8	33
352	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1721-1729.	0.8	40
353	In Vivo Reflectance Confocal Microscopy for the Diagnosis of Melanoma and Melanotic Macules of the Lip. <i>JAMA Dermatology</i> , 2017, 153, 882.	2.0	26
354	Title is missing!. , 2017, , .		82
355	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9508-9508.	0.8	98
356	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9541-9541.	0.8	2
357	Preliminary results from the international neoadjuvant melanoma consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9581-9581.	0.8	11
358	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9600-TPS9600.	0.8	4
359	A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types. <i>Oncotarget</i> , 2017, 8, 2807-2815.	0.8	10
360	Conditional survival estimates for cancer patients. <i>Oncotarget</i> , 2017, 8, 84639-84640.	0.8	7

#	ARTICLE	IF	CITATIONS
361	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. Journal of Clinical Oncology, 2017, 35, 51-51.	0.8	0
362	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. Journal of Clinical Oncology, 2017, 35, 9558-9558.	0.8	0
363	Abstract 2206: Proteome phenotype of stage III metastatic melanoma and response to MEK inhibition. , 2017, , .		0
364	Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis. , 2017, , .		0
365	Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. , 2017, , .		0
366	Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell and Melanoma Research, 2016, 29, 444-452.	1.5	3
367	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. American Journal of Surgical Pathology, 2016, 40, 786-795.	2.1	41
368	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. British Journal of Dermatology, 2016, 175, 1073-1075.	1.4	88
369	Dermoscopy and <i>in vivo</i> confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light-coloured skin lesions. British Journal of Dermatology, 2016, 175, 1311-1319.	1.4	53
370	Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. British Journal of Dermatology, 2016, 175, 1290-1300.	1.4	48
371	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 2016, 8, 369ra177.	5.8	33
372	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. European Journal of Cancer, 2016, 62, 76-85.	1.3	178
373	The molecular profile of metastatic melanoma in Australia. Pathology, 2016, 48, 188-193.	0.3	26
374	Critical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology, 2016, 23, 2753-2761.	0.7	44
375	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. Annals of Surgical Oncology, 2016, 23, 2658-2663.	0.7	17
376	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 2016, 48, 574-580.	0.3	59
377	SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens. Pathology, 2016, 48, 626-628.	0.3	16
378	Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. Pathology, 2016, 48, 395-397.	0.3	15

#	ARTICLE	IF	CITATIONS
379	Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1176-1186.e4.	0.6	38
380	Atypical Ewing sarcoma breakpoint region 1 fluorescence <i>in situ</i> hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. <i>Histopathology</i> , 2016, 69, 1000-1011.	1.6	12
381	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncology</i> , 2016, 5, e1238557.	2.1	113
382	Lethal melanoma in children: a clinicopathological study of 12 cases. <i>Pathology</i> , 2016, 48, 705-711.	0.3	8
383	Angiomatoid Spitz naevus: novel observations and clues to diagnosis of a rare variant. <i>Pathology</i> , 2016, 48, 739-742.	0.3	1
384	<i>BRAF</i> ^{V600E} and <i>NRAS</i> ^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. <i>Histopathology</i> , 2016, 69, 680-686.	1.6	28
385	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. <i>Histopathology</i> , 2016, 69, 25-34.	1.6	177
386	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2mm in Thickness): Analysis of 2131 Patients Treated at a Single Center. <i>Annals of Surgical Oncology</i> , 2016, 23, 1071-1081.	0.7	31
387	The regenerating naevus. <i>Pathology</i> , 2016, 48, 108-112.	0.3	13
388	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3915-3923.	3.2	91
389	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. <i>Pathology</i> , 2016, 48, 261-266.	0.3	39
390	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. <i>Modern Pathology</i> , 2016, 29, 347-358.	2.9	43
391	Advances in melanoma: revolutionary progress delivering improved patient management and outcomes. <i>Pathology</i> , 2016, 48, 105-107.	0.3	4
392	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.3	19
393	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1082-1089.	0.7	43
394	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2016, 127, 435-444.	1.4	55
395	Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. <i>Modern Pathology</i> , 2016, 29, 122-130.	2.9	25
396	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 245-254.	0.3	82

#	ARTICLE	IF	CITATIONS
397	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.. Journal of Clinical Oncology, 2016, 34, 9583-9583.	0.8	9
398	A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).. Journal of Clinical Oncology, 2016, 34, TPS9591-TPS9591.	0.8	6
399	PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. Oncotarget, 2016, 7, 77010-77020.	0.8	44
400	Abstract A024: Protein microarrays for the immunological profiling of melanoma. , 2016, , .		0
401	Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition. , 2016, , .		0
402	3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. European Journal of Cancer, 2015, 51, S666.	1.3	6
403	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.3	9
404	A recurrent germline <i>BAP1</i> mutation and extension of the <i>BAP1</i> tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 2015, 88, 267-272.	1.0	81
405	Clinical activity of the <i>MEK</i> inhibitor trametinib in metastatic melanoma containing <i>BRAF</i> kinase fusion. Pigment Cell and Melanoma Research, 2015, 28, 607-610.	1.5	70
406	BAP1-inactivated Spitzoid Naevi. American Journal of Surgical Pathology, 2015, 39, 722.	2.1	16
407	Punch biopsy of melanoma causing tumour cell implantation: Another peril of utilising partial biopsies for melanocytic tumours. Australasian Journal of Dermatology, 2015, 56, 227-231.	0.4	1
408	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with <i>BRAF</i> or combined <i>BRAF</i> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	2.0	40
409	Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?. Melanoma Management, 2015, 2, 15-19.	0.1	4
410	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	0.8	278
411	Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Research, 2015, 25, 91-94.	0.6	22
412	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes, 2015, 8, 192.	0.6	15
413	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Åmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2015, 22, 2972-2977.	0.7	13
414	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal of the American Academy of Dermatology, 2015, 72, 809-815.e1.	0.6	39

#	ARTICLE	IF	CITATIONS
415	RIP1 Kinase Is an Oncogenic Driver in Melanoma. <i>Cancer Research</i> , 2015, 75, 1736-1748.	0.4	63
416	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 98-105.	3.2	60
417	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <i>Lung Cancer</i> , 2015, 89, 181-188.	0.9	253
418	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1680-1692.	1.9	32
419	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.4	270
420	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	1.3	269
421	Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. <i>International Journal of Cancer</i> , 2015, 136, 863-874.	2.3	67
422	Multiple checkpoints on the long road towards cancer immunotherapy. <i>Immunology and Cell Biology</i> , 2015, 93, 323-325.	1.0	9
423	Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases. <i>Annals of Surgical Oncology</i> , 2015, 22, 1959-1966.	0.7	73
424	Role of frozen section analysis in nodular thyroid pathology. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2015, 132, 67-70.	0.4	19
425	Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor. <i>Annals of Surgical Oncology</i> , 2015, 22, 1598-1603.	0.7	20
426	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
427	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTC 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1049-1060.	5.1	173
428	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015, 2, 671-680.	2.7	86
429	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	3.2	120
430	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	2.9	37
431	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 475-481.	0.7	131
432	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. <i>Molecular Cancer Research</i> , 2015, 13, 670-680.	1.5	22

#	ARTICLE	IF	CITATIONS
433	<sc>PD</sc>â€1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€PD</sc>â€1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	1.5	356
434	New <i>RAS</i>-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e52-e56.	0.8	28
435	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	2.9	76
436	Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 2015, 47, 1408-1410.	9.4	90
437	A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine, 2015, 373, 1618-1626.	13.9	469
438	Eruptive disseminated <sc>S</sc>pitz naevus (<sc>EDSN</sc>) in a young girl of Indian origin. Australasian Journal of Dermatology, 2015, 56, 134-136.	0.4	8
439	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	9.4	221
440	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	3.3	146
441	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 2015, 8, 111-118.	3.1	17
442	MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with <i>BRAF</i> mutation and patient prognosis. Pigment Cell and Melanoma Research, 2015, 28, 254-266.	1.5	59
443	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitorâ€Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 2015, 135, 532-541.	0.3	79
444	Abstract 2968: Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations. Cancer Research, 2015, 75, 2968-2968.	0.4	2
445	Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.. Journal of Clinical Oncology, 2015, 33, 9011-9011.	0.8	11
446	Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.. Journal of Clinical Oncology, 2015, 33, TPS9091-TPS9091.	0.8	6
447	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 2015, 6, 39891-39907.	0.8	40
448	Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events.. Journal of Clinical Oncology, 2015, 33, e20033-e20033.	0.8	0
449	PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials.. Journal of Clinical Oncology, 2015, 33, e20011-e20011.	0.8	0
450	BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.. Journal of Clinical Oncology, 2015, 33, 9008-9008.	0.8	2

#	ARTICLE	IF	CITATIONS
451	Abstract 56: Receptor-Interacting protein kinase 1 functions as an oncogenic regulator in human melanoma. , 2015, , .		0
452	Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance. , 2015, , .		0
453	Abstract 4718: Inositol polyphosphate 4-phosphatase II activates PI3K/SGK3 signaling to promote proliferation of human melanoma cells. , 2015, , .		0
454	Reply to M. Perier-Muzet et al. Journal of Clinical Oncology, 2014, 32, 3203-3204.	0.8	3
455	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	2.9	78
456	A novel hypoxia-associated subset of FN1 ^{high} MITFlow melanoma cells: identification, characterization, and prognostic value. Modern Pathology, 2014, 27, 1088-1100.	2.9	20
457	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	2.9	18
458	Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 2014, 33, 4756-4766.	2.6	29
459	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. British Journal of Cancer, 2014, 111, 1678-1679.	2.9	9
460	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 2014, 5, 5694.	5.8	295
461	Pharmacologically Antagonizing the CXCR4-CXCL12 Chemokine Pathway with AMD3100 Inhibits Sunlight-Induced Skin Cancer. Journal of Investigative Dermatology, 2014, 134, 1091-1100.	0.3	54
462	Atypical naevus spilus: detection byin vivoconfocal microscopy. Clinical and Experimental Dermatology, 2014, 39, 616-619.	0.6	2
463	Surveillance for treatment failure of lentigo maligna with dermoscopy andin vivoconfocal microscopy: new descriptors. British Journal of Dermatology, 2014, 170, 1305-1312.	1.4	55
464	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 β and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.4	161
465	Inpatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	2.1	66
466	Atypical Spitzoid neoplasms. Melanoma Research, 2014, 24, 437-447.	0.6	25
467	Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up. American Journal of Surgical Pathology, 2014, 38, 934-940.	2.1	142
468	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 2014, 46, 193-198.	0.3	19

#	ARTICLE	IF	CITATIONS
469	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. <i>Cancer Discovery</i> , 2014, 4, 69-79.	7.7	141
470	Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1106-1116.	1.5	16
471	Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. <i>British Journal of Dermatology</i> , 2014, 170, 52-58.	1.4	72
472	Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 407-421.	1.7	6
473	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt435-djt435.	3.0	64
474	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977.	3.2	447
475	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. <i>Methods in Molecular Biology</i> , 2014, 1102, 287-324.	0.4	78
476	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. <i>Journal of Immunology</i> , 2014, 192, 2505-2513.	0.4	69
477	Diffuse melanosis cutis in the setting of BRAFV600E metastatic melanoma. <i>International Journal of Dermatology</i> , 2014, 53, 1409-1411.	0.5	3
478	A light shines on melanoma metastagenesis. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 696-697.	1.5	0
479	Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. <i>Oncogene</i> , 2014, 33, 1158-1166.	2.6	60
480	Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. <i>Cancer Discovery</i> , 2014, 4, 423-433.	7.7	242
481	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823.	0.8	20
482	Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. <i>Modern Pathology</i> , 2014, 27, 936-944.	2.9	46
483	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 292-299.	2.9	93
484	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. <i>Annals of Surgical Oncology</i> , 2014, 21, 3108-3116.	0.7	33
485	Pathology Review Significantly Affects Diagnosis and Treatment of Melanoma Patients: An Analysis of 5011 Patients Treated at a Melanoma Treatment Center. <i>Annals of Surgical Oncology</i> , 2014, 21, 2245-2251.	0.7	35
486	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. <i>Human Molecular Genetics</i> , 2014, 23, 226-238.	1.4	96

#	ARTICLE	IF	CITATIONS
487	Primary oesophageal melanoma - a case report. <i>World Journal of Surgical Oncology</i> , 2014, 12, 77.	0.8	5
488	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. <i>Neuro-Oncology</i> , 2014, 16, 1499-1509.	0.6	65
489	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 111-120.	1.3	127
490	The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (≥4 mm in Thickness). <i>Annals of Surgery</i> , 2014, 260, 1095-1102.	2.1	12
491	Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2014, 260, 149-157.	2.1	36
492	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014, 1, 165-172.	0.1	5
493	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling. <i>PLoS ONE</i> , 2014, 9, e94748.	1.1	35
494	A highly recurrent RPS27 5'UTR mutation in melanoma. <i>Oncotarget</i> , 2014, 5, 2912-2917.	0.8	60
495	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. <i>Oncotarget</i> , 2014, 5, 10127-10139.	0.8	31
496	Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. <i>Oncotarget</i> , 2014, 5, 11237-11251.	0.8	34
497	Metastatic Melanoma. , 2014, , 529-567.		0
498	Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9004-9004.	0.8	0
499	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation-positive melanoma with metastases to the brain (BRV116521).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9112-TPS9112.	0.8	0
500	Reflectance confocal microscopy for diagnosis of mammary and extramammary Paget's disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e24-9.	1.3	36
501	Improving Management and Patient Care in Lentigo Maligna by Mapping With In Vivo Confocal Microscopy. <i>JAMA Dermatology</i> , 2013, 149, 692.	2.0	114
502	Reproducibility of AJCC Staging Parameters in Primary Cutaneous Melanoma: An Analysis of 4,924 Cases. <i>Annals of Surgical Oncology</i> , 2013, 20, 3969-3975.	0.7	20
503	Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 499-508.	1.5	37
504	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 852-860.	1.5	48

#	ARTICLE	IF	CITATIONS
505	The important role of radiation treatment in the management of Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2013, 169, 975-982.	1.4	28
506	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1164-1165.	0.5	2
507	Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 179-184.	0.5	22
508	Mitotic rate in melanoma should be recorded as the number of mitoses per mm ² (not per high power) <i>Tj ETQq0 0 0rgBT /Overlock 10 T</i>	0.9	7
509	Safety and tolerability of an intratumorally injected DNzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). <i>Lancet, The</i> , 2013, 381, 1835-1843.	6.3	87
510	Margins of excision and prognostic factors for cutaneous eyelid melanomas. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2013, 66, 1066-1073.	0.5	42
511	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. <i>British Journal of Cancer</i> , 2013, 108, 924-931.	2.9	55
512	Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1269-1277.	0.3	44
513	Premalignancy: The lull before the storm. <i>Pathology</i> , 2013, 45, 207-208.	0.3	2
514	Data Set for Pathology Reporting of Cutaneous Invasive Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1797-1814.	2.1	106
515	Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1387-1394.	2.1	96
516	BAP1 expression in cutaneous melanoma: a pilot study. <i>Pathology</i> , 2013, 45, 606-609.	0.3	30
517	Tumours associated with BAP1 mutations. <i>Pathology</i> , 2013, 45, 116-126.	0.3	242
518	Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. <i>Pathology</i> , 2013, 45, 1-3.	0.3	2
519	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. <i>Pathology</i> , 2013, 45, 55-61.	0.3	15
520	Dermoscopic Evaluation of Nodular Melanoma. <i>JAMA Dermatology</i> , 2013, 149, 699.	2.0	103
521	Prominent angiotropism in a small atypical spitzoid dysplastic melanocytic naevus: what is its significance?. <i>Pathology</i> , 2013, 45, 701-703.	0.3	2
522	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e25564.	2.1	6

#	ARTICLE	IF	CITATIONS
523	Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 326-337.	1.5	33
524	Asymptomatic linear pigmentation of the skin. <i>International Journal of Dermatology</i> , 2013, 52, 935-937.	0.5	3
525	Biospecimen banking: The pathway to personalized medicine for patients with cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 681-682.	0.8	10
526	Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 708-722.	1.5	12
527	Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries. <i>Journal of Surgical Oncology</i> , 2013, 108, 129-135.	0.8	39
528	p16 ^{INK4a} deficiency promotes DNA hyperreplication and genetic instability in melanocytes. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 236-246.	1.5	18
529	<i>BRAF/NRAS</i> Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. <i>Clinical Cancer Research</i> , 2013, 19, 4589-4598.	3.2	115
530	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. <i>Nature Communications</i> , 2013, 4, 1508.	5.8	67
531	AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. <i>Cell Death and Disease</i> , 2013, 4, e914-e914.	2.7	55
532	Recent insights into the molecular pathogenesis of mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2013, 66, 496-505.	1.0	32
533	Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. <i>Expert Review of Dermatology</i> , 2013, 8, 195-214.	0.3	7
534	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 509-517.	0.3	156
535	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	2.1	289
536	Risk Assessment for Atypical Spitzoid Melanocytic Neoplasms Using FISH to Identify Chromosomal Copy Number Aberrations. <i>American Journal of Surgical Pathology</i> , 2013, 37, 676-684.	2.1	175
537	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. <i>Annals of Surgery</i> , 2013, 258, 152-157.	2.1	56
538	Abstract 3876: TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma.. , 2013, , .		1
539	Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTC 0.1.02/TROG 02.01).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9001-9001.	0.8	8
540	Abstract B8: Galectin-1 expressed in human melanoma is bound to cancer stem cells: A driver for metastatic progression and target for antimetastatic cancer therapy. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
541	Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2678-2683.	0.8	691
542	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 1386-1394.	3.2	589
543	SOX2 contributes to melanoma cell invasion. <i>Laboratory Investigation</i> , 2012, 92, 362-370.	1.7	85
544	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. <i>Oncolmmunology</i> , 2012, 1, 997-999.	2.1	27
545	Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. <i>Modern Pathology</i> , 2012, 25, 828-837.	2.9	43
546	Intratumoral Molecular Heterogeneity in a <i>BRAF</i> -Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2704-2708.	1.9	78
547	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3242-3249.	3.2	405
548	Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 274-283.	0.3	52
549	Peritoneal melanosis associated with metastatic melanoma involving the omentum. <i>Pathology</i> , 2012, 44, 255-257.	0.3	15
550	Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. <i>Annals of Surgery</i> , 2012, 255, 1165-1170.	2.1	62
551	Endocrine mucin producing sweat gland carcinoma: a clinicopathological analysis of three cases. <i>Pathology</i> , 2012, 44, 568-571.	0.3	14
552	Cellular blue naevus involving the urinary bladder. <i>Pathology</i> , 2012, 44, 664-668.	0.3	5
553	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2012, 255, 128-133.	2.1	103
554	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 589-597.	5.1	253
555	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. <i>Cell</i> , 2012, 150, 1135-1146.	13.5	688
556	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3325-3334.	0.7	59
557	Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3310-3312.	0.7	7
558	Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma. <i>Molecular Genetics and Metabolism</i> , 2012, 106, 127-130.	0.5	23

#	ARTICLE	IF	CITATIONS
559	In Vivo Confocal Microscopy for Diagnosis of Melanoma and Basal Cell Carcinoma Using a Two-Step Method: Analysis of 710 Consecutive Clinically Equivocal Cases. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2386-2394.	0.3	252
560	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2012, 167, 1153-1160.	1.4	163
561	Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. <i>Annals of Surgical Oncology</i> , 2012, 19, 1024-1033.	0.7	45
562	Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2226-2234.	0.3	50
563	E-cadherin expression in the epithelial components of mammary phyllodes tumors. <i>Human Pathology</i> , 2012, 43, 2117-2123.	1.1	16
564	The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis <i>in vivo</i> and reduces skin cancer cell migration <i>in vitro</i> . <i>Journal of Pathology</i> , 2012, 226, 451-462.	2.1	36
565	Melanoma whole-exome sequencing identifies V600E-BRAF amplification-mediated acquired B-RAF inhibitor resistance. <i>Nature Communications</i> , 2012, 3, 724.	5.8	567
566	A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 888-897.	1.9	45
567	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. <i>Cancer</i> , 2012, 118, 4519-4529.	2.0	29
568	Involvement of β -catenin and E-cadherin in the development of mammary phyllodes tumours. <i>Histopathology</i> , 2012, 61, 667-674.	1.6	17
569	Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. <i>Histopathology</i> , 2012, 61, 889-898.	1.6	42
570	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. <i>Histopathology</i> , 2012, 61, 702-710.	1.6	29
571	The absence of <i>Bcr</i> exacerbates photocarcinogenesis. <i>Experimental Dermatology</i> , 2012, 21, 599-604.	1.4	21
572	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. <i>British Journal of Dermatology</i> , 2012, 166, 1319-1326.	1.4	8
573	Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 1774-1781.	0.7	39
574	Sentinel Lymph Nodes Containing Very Small ($\leq 0.1\text{ mm}$) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative. <i>Annals of Surgical Oncology</i> , 2012, 19, 1089-1099.	0.7	45
575	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1782-1789.	0.7	30
576	Identification of <i>TFG</i> (TRK fused gene) as a putative metastatic melanoma tumor suppressor gene. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 452-461.	1.5	25

#	ARTICLE	IF	CITATIONS
577	Melanoma - a management guide for GPs. Australian Family Physician, 2012, 41, 470-3.	0.5	6
578	Melanoma Pathology: Important Issues for Clinicians Involved in the Multidisciplinary Care of Melanoma Patients. Surgical Oncology Clinics of North America, 2011, 20, 19-37.	0.6	19
579	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology, 2011, 5, 124-136.	2.1	135
580	Cancerâ€™testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 2011, 47, 460-469.	1.3	49
581	<i>BRAF</i> mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell and Melanoma Research, 2011, 24, 345-351.	1.5	180
582	The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 2011, 43, 657-671.	0.3	40
583	Follicular dendritic cell sarcoma of the lung: a report of two cases highlighting its pathological features and diagnostic pitfalls. Pathology, 2011, 43, 67-70.	0.3	4
584	Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. Annals of Surgery, 2011, 253, 1155-1164.	2.1	34
585	BRM and BRC1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. British Journal of Dermatology, 2011, 164, 1221-1227.	1.4	30
586	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology, 2011, 58, 886-895.	1.6	19
587	Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2011, 18, 3292-3299.	0.7	24
588	The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1999-2004.	3.3	13
589	Selective Loss of Wild-Type p16INK4a Expression in Human Nevi. Journal of Investigative Dermatology, 2011, 131, 2329-2332.	0.3	9
590	Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. Journal of Clinical Oncology, 2011, 29, 1239-1246.	0.8	942
591	Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.	0.8	0
592	MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15840-15845.	3.3	168
593	Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2011, 131, 1631-1638.	0.3	153
594	Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).. Journal of Clinical Oncology, 2011, 29, 8542-8542.	0.8	6

#	ARTICLE	IF	CITATIONS
595	Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?. Archives of Pathology and Laboratory Medicine, 2011, 135, 300-306.	1.2	61
596	State of the Art, Nomenclature, and Points of Consensus and Controversy Concerning Benign Melanocytic Lesions: Outcome of an International Workshop. Advances in Anatomic Pathology, 2010, 17, 73-90.	2.4	86
597	Location of Melanoma Metastases in Sentinel Lymph Nodes: What are the Implications for Histologic Processing of Sentinel Lymph Nodes in Routine Practice?. American Journal of Surgical Pathology, 2010, 34, 127-129.	2.1	5
598	Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery, 2010, 251, 1188-1189.	2.1	1
599	Diagnostic value of 8.5â€%T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. Melanoma Research, 2010, 20, 311-317.	0.6	7
600	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	0.7	68
601	The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999.	0.7	9
602	Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma. Annals of Surgical Oncology, 2010, 17, 3015-3020.	0.7	30
603	Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model. Annals of Surgical Oncology, 2010, 17, 1995-2005.	0.7	34
604	Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. Diagnostic Histopathology, 2010, 16, 401-408.	0.2	6
605	An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 2010, 358, 23-34.	0.6	22
606	Re-evaluation of a Scoring System to Predict Nonsentinel-Node Metastasis and Prognosis in Melanoma Patients. Journal of the American College of Surgeons, 2010, 211, 522-525.	0.2	12
607	Prognostic factors in cutaneous desmoplastic melanoma. Cancer, 2010, 116, 4130-4138.	2.0	109
608	Melanoma exhibiting cartilaginous differentiation. Histopathology, 2010, 56, 815-821.	1.6	11
609	Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology, 2010, 56, 768-774.	1.6	41
610	p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. Histopathology, 2010, 56, 868-875.	1.6	30
611	The Impact of In Vivo Reflectance Confocal Microscopy on the Diagnostic Accuracy of Lentigo Maligna and Equivocal Pigmented and Nonpigmented Macules of the Face. Journal of Investigative Dermatology, 2010, 130, 2080-2091.	0.3	261
612	Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. Pathology, 2010, 42, 284-286.	0.3	15

#	ARTICLE	IF	CITATIONS
613	Cutaneous Metastases. , 2010, , 637-650.		2
614	Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology. PLoS ONE, 2010, 5, e11965.	1.1	18
615	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. Melanoma Research, 2010, 20, 203-211.	0.6	8
616	Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, E46; author reply E47.	3.3	4
617	Retroperitoneal Inflammatory Liposarcoma in a Patient with Non-Hodgkin Lymphoma: A Report Highlighting Diagnostic Pitfalls. Pathology Research International, 2010, 2010, 1-4.	1.4	2
618	Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes. Journal of Clinical Oncology, 2010, 28, 4441-4449.	0.8	111
619	Lymphoma occurring in patients with cutaneous melanoma. Journal of Clinical Pathology, 2010, 63, 777-781.	1.0	13
620	Morphologic Features of Melanophages Under In Vivo Reflectance Confocal Microscopy. Archives of Dermatology, 2010, 146, 492-8.	1.7	36
621	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. Pathology, 2010, 42, 287-289.	0.3	13
622	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 2010, 23, 45-53.	2.9	68
623	IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 2010, 141, 717-727.	13.5	60
624	High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell and Melanoma Research, 2010, 23, 137-140.	1.5	21
625	Genetic and morphologic features for melanoma classification. Pigment Cell and Melanoma Research, 2010, 23, 763-770.	1.5	130
626	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncology, The, 2010, 11, 391-400.	5.1	20
627	Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.. Journal of Clinical Oncology, 2010, 28, 8548-8548.	0.8	4
628	Histologically Ambiguous (â€œBorderlineâ€œ) Primary Cutaneous Melanocytic Tumors: Approaches to Patient Management Including the Roles of Molecular Testing and Sentinel Lymph Node Biopsy. Archives of Pathology and Laboratory Medicine, 2010, 134, 1770-1777.	1.2	47
629	Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. Ochsner Journal, 2010, 10, 66-74.	0.5	17
630	LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis. PLoS ONE, 2009, 4, e4430.	1.1	62

#	ARTICLE	IF	CITATIONS
631	Cutaneous metastasis of epithelioid haemangioendothelioma. <i>Pathology</i> , 2009, 41, 585-587.	0.3	4
632	Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5614-5619.	0.8	91
633	Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2009, 62, 1016-1020.	1.0	32
634	Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors. <i>International Journal of Surgical Pathology</i> , 2009, 17, 361-367.	0.4	40
635	Cytological features of melanoma in exfoliative fluid specimens. <i>Journal of Clinical Pathology</i> , 2009, 62, 638-643.	1.0	9
636	Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. <i>Journal of Clinical Pathology</i> , 2009, 62, 915-919.	1.0	41
637	Phyllodes tumours of the breast: A clinicopathological analysis of 65 cases from a single institution. <i>Breast</i> , 2009, 18, 165-170.	0.9	92
638	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. <i>Cancer</i> , 2009, 115, 5026-5037.	2.0	75
639	So-called "malignant blue nevus". <i>Cancer</i> , 2009, 115, 2949-2955.	2.0	66
640	Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 441-448.	1.1	57
641	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1713-1742.	3.3	159
642	Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. <i>Histopathology</i> , 2009, 54, 462-470.	1.6	91
643	Evaluation of the Clonal Origin of Multiple Primary Melanomas Using Molecular Profiling. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1972-1982.	0.3	27
644	Functional RET G691S polymorphism in cutaneous malignant melanoma. <i>Oncogene</i> , 2009, 28, 3058-3068.	2.6	62
645	Surgical Strategies and Histopathologic Issues in the Management of Lentigo Maligna. <i>Annals of Surgical Oncology</i> , 2009, 16, 1456-1458.	0.7	7
646	Surgery for melanoma metastases of the gastrointestinal tract: Indications and results. <i>European Journal of Surgical Oncology</i> , 2009, 35, 313-319.	0.5	87
647	The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. <i>Molecular Cancer</i> , 2009, 8, 4.	7.9	55
648	Elemental bio-imaging of melanoma in lymph node biopsies. <i>Analyst</i> , 2009, 134, 450-453.	1.7	51

#	ARTICLE	IF	CITATIONS
649	Radiation Recall Dermatitis After Pre-Sensitization With Pegylated Liposomal Doxorubicin. <i>Cancer Investigation</i> , 2009, 27, 397-401.	0.6	8
650	Cutaneous melanoma in the era of molecular profiling. <i>Lancet, The</i> , 2009, 374, 362-365.	6.3	100
651	Pigmented Epithelioid Melanocytoma: Favorable Outcome After 5-year Follow-up. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1778-1782.	2.1	110
652	Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2009, 249, 641-647.	2.1	45
653	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. <i>Annals of Surgery</i> , 2009, 249, 473-480.	2.1	61
654	Sentinel Node Status Prediction by Four Statistical Models. <i>Annals of Surgery</i> , 2009, 250, 964-969.	2.1	28
655	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1386-1395.	2.1	95
656	False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. <i>Melanoma Research</i> , 2009, 19, 94-99.	0.6	53
657	Blue Nevi and Related Lesions. <i>Advances in Anatomic Pathology</i> , 2009, 16, 365-382.	2.4	141
658	Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. <i>Pathology</i> , 2009, 41, 383-387.	0.3	92
659	Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. <i>Pathology</i> , 2009, 41, 105-117.	0.3	35
660	The Role of Intra-operative Pathological Evaluation in the Management of Musculoskeletal Tumours. <i>Recent Results in Cancer Research</i> , 2009, 179, 11-24.	1.8	10
661	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. <i>Histopathology</i> , 2008, 52, 242-242.	1.6	5
662	The advantage of using a synoptic pathology report format for cutaneous melanoma. <i>Histopathology</i> , 2008, 52, 130-138.	1.6	82
663	Desmoplastic neurotropic melanoma. <i>Cancer</i> , 2008, 113, 2770-2778.	2.0	131
664	Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management. <i>Annals of Surgical Oncology</i> , 2008, 15, 323-332.	0.7	28
665	Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). <i>Annals of Surgical Oncology</i> , 2008, 15, 302-309.	0.7	116
666	The Complex Relationships Between Sentinel Node Positivity, Patient Age, and Primary Tumor Desmoplasia: Analysis of 2303 Melanoma Patients Treated at a Single Center. <i>Annals of Surgical Oncology</i> , 2008, 15, 630-637.	0.7	47

#	ARTICLE	IF	CITATIONS
667	Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma-Mass Spectrometry. <i>Annals of Surgical Oncology</i> , 2008, 15, 934-940.	0.7	8
668	Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2008, 15, 2749-2756.	0.7	48
669	Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 2509-2518.	0.7	95
670	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. <i>British Journal of Cancer</i> , 2008, 98, 1085-1093.	2.9	56
671	Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 787-789.	0.6	15
672	Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. <i>Histopathology</i> , 2008, 53, 345-345.	1.6	5
673	The detection and significance of melanoma micrometastases in sentinel nodes. <i>Surgical Oncology</i> , 2008, 17, 165-174.	0.8	48
674	Pathologic examination of sentinel lymph nodes from melanoma patients. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 100-111.	1.0	102
675	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1-10.	1.6	5
676	Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. <i>Clinical Cancer Research</i> , 2008, 14, 638-645.	3.2	141
677	Cytologic Features of Metastatic and Recurrent Melanoma in Patients with Primary Cutaneous Desmoplastic Melanoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 715-723.	0.4	24
678	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. <i>Future Oncology</i> , 2008, 4, 535-551.	1.1	20
679	Tumoural calcium pyrophosphate dihydrate crystal deposition disease (tophaceous pseudogout) of the hand: a report of two cases including one with a previously unreported associated florid reactive myofibroblastic proliferation. <i>Pathology</i> , 2008, 40, 719-722.	0.3	8
680	Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1396-1403.	2.1	69
681	False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology. <i>Annals of Surgery</i> , 2008, 247, 1003-1010.	2.1	67
682	The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1106-1107.	2.1	11
683	Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. <i>Melanoma Research</i> , 2008, 18, 365-366.	0.6	0
684	Merkel cell carcinoma with fibrosarcomatous differentiation. <i>Pathology</i> , 2008, 40, 314-316.	0.3	20

#	ARTICLE	IF	CITATIONS
685	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. <i>Annals of Oncology</i> , 2007, 18, 806-808.	0.6	17
686	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 3825-3830.	3.2	67
687	Low meprin A expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. <i>Journal of Clinical Pathology</i> , 2007, 60, 622-626.	1.0	19
688	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. <i>American Journal of Clinical Pathology</i> , 2007, 127, 385-397.	0.4	72
689	New evidence for geographic variation in the role of human papillomavirus in tonsillar carcinogenesis. <i>Pathology</i> , 2007, 39, 217-222.	0.3	35
690	Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. <i>Pathology</i> , 2007, 39, 551-557.	0.3	41
691	Subungual Melanoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1902-1912.	2.1	157
692	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 889-890.	0.6	16
693	Re: NM patients and SN. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2007, 5, 320.	0.8	0
694	Paratesticular rhabdomyoma. <i>Pathology</i> , 2007, 39, 367-369.	0.3	5
695	Primary Melanoma of the Lung. <i>American Surgeon</i> , 2007, 73, 937-938.	0.4	2
696	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. <i>Modern Pathology</i> , 2007, 20, 416-426.	2.9	169
697	Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004. <i>Annals of Surgical Oncology</i> , 2007, 14, 1943-1952.	0.7	101
698	Epithelioid and spindle cell haemangioma of bone. <i>Skeletal Radiology</i> , 2007, 36, 50-57.	1.2	12
699	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study. <i>Journal of Clinical Oncology</i> , 2007, 25, 8509-8509.	0.8	0
700	Myopericytoma: a unifying term for a spectrum of tumours that show overlapping features with myofibroma. A review of 14 cases. <i>Journal of Clinical Pathology</i> , 2006, 59, 67-73.	1.0	146
701	Surgical Management of Primary Cutaneous Melanoma: Excision Margins and the Role of Sentinel Lymph Node Examination. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 301-318.	0.6	26
702	Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. <i>Human Pathology</i> , 2006, 37, 1286-1294.	1.1	71

#	ARTICLE	IF	CITATIONS
703	Primary Melanoma of the Lung. , 2006, , 293-297.		9
704	The importance of mitotic rate as a prognostic factor for localized primary cutaneous melanoma. Journal of Cutaneous Pathology, 2006, 33, 395-396.	0.7	22
705	Pravastatin-induced lichenoid drug eruption. Australasian Journal of Dermatology, 2006, 47, 57-59.	0.4	44
706	LETTERS TO THE EDITOR. Australasian Journal of Dermatology, 2006, 47, 71-73.	0.4	27
707	An unusual variant of intraneural ganglion of the common peroneal nerve. Skeletal Radiology, 2006, 35, 165-171.	1.2	22
708	Myxoid variant of adrenocortical carcinoma: Report of a unique case. Pathology International, 2006, 56, 89-94.	0.6	25
709	Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. Journal of Clinical Pathology, 2006, 60, 1051-1056.	1.0	12
710	The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology, 2006, 38, 287-301.	0.3	109
711	Survival in Patients With Desmoplastic Melanoma. Journal of Clinical Oncology, 2006, 24, e12-e12.	0.8	20
712	Surgical biopsy with intra-operative frozen section. Journal of Bone and Joint Surgery: British Volume, 2006, 88-B, 1207-1211.	3.4	53
713	A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 904-913.	2.9	102
714	Condylomata acuminata of the urinary bladder with HPV 11. Pathology, 2005, 37, 176-178.	0.3	10
715	Histopathologic Excision Margin Affects Local Recurrence Rate. Annals of Surgery, 2005, 241, 326-333.	2.1	57
716	Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour?. Melanoma Research, 2005, 15, 531-537.	0.6	44
717	Melanoma Metastases in Regional Lymph Nodes Are Accurately Detected by Proton Magnetic Resonance Spectroscopy of Fine-Needle Aspirate Biopsy Samples. Annals of Surgical Oncology, 2005, 12, 943-949.	0.7	20
718	A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 597-608.	0.7	67
719	Desmoplastic Melanoma: A Heterogeneous Entity in Which Subclassification as ?Pure? or ?Mixed? May Have Important Prognostic Significance. Annals of Surgical Oncology, 2005, 12, 197-199.	0.7	49
720	Borderline lepromatous leprosy presenting as a single cutaneous plaque. Australasian Journal of Dermatology, 2005, 46, 181-183.	0.4	11

#	ARTICLE	IF	CITATIONS
721	Eccrine porocarcinoma of the upper eyelid. <i>Australasian Journal of Dermatology</i> , 2005, 46, 278-281.	0.4	33
722	Intraoperative Frozen-Section Evaluation Can Reduce Accuracy of Pathologic Assessment of Sentinel Nodes in Melanoma Patients. <i>Journal of the American College of Surgeons</i> , 2005, 201, 821-823.	0.2	32
723	Transforming growth factor- β 1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 898-906.	2.0	70
724	Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2005, 12, 18-23.	0.7	99
725	Selective Sentinel Lymphadenectomy: Progress to Date and Prospects for the Future. <i>Cancer Treatment and Research</i> , 2005, 127, 269-287.	0.2	17
726	Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2005, 58, 185-189.	1.0	61
727	Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. <i>Journal of Clinical Pathology</i> , 2005, 58, 600-604.	1.0	26
728	Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. <i>Journal of Clinical Pathology</i> , 2005, 58, 1163-1169.	1.0	74
729	Cutaneous melanoma. <i>Lancet, The</i> , 2005, 365, 687-701.	6.3	511
730	Cutaneous melanoma. <i>Lancet, The</i> , 2005, 365, 2003.	6.3	4
731	Cutaneous melanoma. <i>Lancet, The</i> , 2005, 365, 2004-2005.	6.3	2
732	In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. <i>European Journal of Radiology</i> , 2005, 53, 506-513.	1.2	25
733	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. <i>Annals of Surgical Oncology</i> , 2005, 12, 429-439.	0.7	109
734	Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4427-4436.	3.2	189
735	Desmoplastic melanoma: a diagnostic trap for the unwary. <i>Pathology</i> , 2004, 36, 445-451.	0.3	90
736	Polymorphous Low-Grade Adenocarcinoma in the Lung: A Case Report. <i>International Journal of Surgical Pathology</i> , 2004, 12, 287-292.	0.4	17
737	Myoid Angioendothelioma of the Spleen. <i>International Journal of Surgical Pathology</i> , 2004, 12, 51-56.	0.4	15
738	Micromorphometric Features of Positive Sentinel Lymph Nodes Predict Involvement of Nonsentinel Nodes in Patients With Melanoma. <i>American Journal of Clinical Pathology</i> , 2004, 122, 532-539.	0.4	117

#	ARTICLE	IF	CITATIONS
739	Unusual case of subcutaneous panniculitis-like T-cell lymphoma. <i>Australasian Journal of Dermatology</i> , 2004, 45, 114-118.	0.4	12
740	Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. <i>Modern Pathology</i> , 2004, 17, 827-831.	2.9	69
741	The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer. <i>Modern Pathology</i> , 2004, 17, 1031-1037.	2.9	8
742	Antimony concentrations in nodal tissue can confirm sentinel node identity. <i>Modern Pathology</i> , 2004, 17, 1191-1197.	2.9	17
743	Parachordoma is not distinguishable from axial chordoma using immunohistochemistry. <i>Pathology International</i> , 2004, 54, 364-370.	0.6	18
744	Progressive visual loss in a patient with presumed temporal arteritis despite treatment: how to make the diagnosis. <i>Clinical and Experimental Ophthalmology</i> , 2004, 32, 335-336.	1.3	6
745	Sentinel node biopsy for melanoma: Where have we been and where are we going?. <i>Annals of Surgical Oncology</i> , 2004, 11, 147S-151S.	0.7	19
746	Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: Evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. <i>Annals of Surgical Oncology</i> , 2004, 11, 174S-178S.	0.7	13
747	Epiphyseal osteoblastoma-like osteosarcoma. <i>Skeletal Radiology</i> , 2004, 33, 46-50.	1.2	14
748	The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. <i>Head and Neck</i> , 2004, 26, 1-9.	0.9	96
749	Sentinel lymph nodes in malignant melanoma: Extended histopathologic evaluation improves diagnostic precision. <i>Cancer</i> , 2004, 101, 2141-2142.	2.0	20
750	The history and future of melanoma staging. <i>Journal of Surgical Oncology</i> , 2004, 86, 224-235.	0.8	18
751	Pathology of melanocytic lesions: New, controversial, and clinically important issues. <i>Journal of Surgical Oncology</i> , 2004, 86, 200-211.	0.8	54
752	Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 829-836.	0.7	71
753	The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up. <i>Annals of Surgical Oncology</i> , 2004, 11, 426-433.	0.7	180
754	The significance of the Wnt pathway in the pathology of human cancers. <i>Pathology</i> , 2004, 36, 120-128.	0.3	246
755	Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: A multicenter study of 185 cases. <i>Human Pathology</i> , 2004, 35, 1053-1057.	1.1	65
756	Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. <i>Pathology</i> , 2004, 36, 561-565.	0.3	18

#	ARTICLE	IF	CITATIONS
757	Frontiers in melanocytic pathology. Pathology, 2004, 36, 385-386.	0.3	11
758	Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. Melanoma Research, 2004, 14, 239.	0.6	1
759	Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck. Annals of Surgery, 2004, 239, 544-552.	2.1	106
760	Immunohistochemical stains fail to increase the detection rate of micrometastatic melanoma in completion regional lymph node dissection specimens. Melanoma Research, 2004, 14, 263-268.	0.6	21
761	Pigmented Epithelioid Melanocytoma. American Journal of Surgical Pathology, 2004, 28, 1114-1115.	2.1	52
762	Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. Pathology, 2004, 36, 419-427.	0.3	71
763	Spitz naevus: diagnostic problems and their management implications. Pathology, 2004, 36, 452-457.	0.3	47
764	Cooperation between surgical oncologists and pathologists: a key element of multidisciplinary care for patients with cancer. Pathology, 2004, 36, 496-503.	0.3	34
765	Alcoholism and dementia. , 2004, , 427-441.		2
766	Failure to Remove True Sentinel Nodes Can Cause Failure of the Sentinel Node Biopsy Technique: Evidence from Antimony Concentrations in False-Negative Sentinel Nodes from Melanoma Patients. Annals of Surgical Oncology, 2004, 11, 174S-178S.	0.7	28
767	Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. American Journal of Clinical Pathology, 2004, 122, 532-9.	0.4	23
768	Melanocytic lesions of the face: diagnostic pitfalls. Annals of the Academy of Medicine, Singapore, 2004, 33, 3-14.	0.2	21
769	Intramuscular dendritic fibromyxolipoma: Myxoid variant of spindle cell lipoma?. Pathology International, 2003, 53, 252-258.	0.6	32
770	Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer, 2003, 97, 1488-1498.	2.0	372
771	Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. International Journal of Cancer, 2003, 106, 553-558.	2.3	209
772	Tumour Angiogenesis and p53 Protein Expression in Mammary Phyllodes Tumors. Modern Pathology, 2003, 16, 1007-1013.	2.9	39
773	Absence of Human Papillomavirus in Tonsillar Squamous Cell Carcinomas from Chinese Patients. American Journal of Pathology, 2003, 163, 2185-2189.	1.9	37
774	Antimony by ICP-MS as a marker for sentinel lymph nodes in melanoma patients. Analyst, The, 2003, 128, 217-219.	1.7	18

#	ARTICLE	IF	CITATIONS
775	Challenging and Unusual Cases. <i>Journal of Clinical Oncology</i> , 2003, 21, 1420-1421.	0.8	0
776	Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4088-4094.	1.8	92
777	Increased expression of apoptotic markers in melanoma. <i>Melanoma Research</i> , 2003, 13, 137-145.	0.6	47
778	Use of multiple cytometric markers improves discrimination between benign and malignant melanocytic lesions. <i>Melanoma Research</i> , 2003, 13, 581-586.	0.6	16
779	Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1571-1576.	2.1	147
780	Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. <i>Melanoma Research</i> , 2003, 13, 259-261.	0.6	27
781	Argyrophilic Staining of Nucleolar Organizer Region Count and Morphometry in Benign and Malignant Melanocytic Lesions. <i>American Journal of Dermatopathology</i> , 2003, 25, 190-197.	0.3	27
782	Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1197-1202.	2.1	102
783	Letter to the Editor. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 98-100.	1.2	3
784	Hormonal Receptors Expression in Epithelial Cells of Mammary Phyllodes Tumors Correlates With Pathologic Grade of the Tumor. <i>American Journal of Clinical Pathology</i> , 2002, 118, 522-526.	0.4	77
785	Increased p53 Protein Expression in Malignant Mammary Phyllodes Tumors. <i>Modern Pathology</i> , 2002, 15, 734-740.	2.9	70
786	Spitz naevus versus spitzoid melanoma: when and how can they be distinguished?. <i>Pathology</i> , 2002, 34, 6-12.	0.3	112
787	An unusual pleural spindle cell tumour Part 1. <i>Pathology</i> , 2002, 34, 370-374.	0.3	3
788	Pagetoid spread of melanocytes in Spitz naevi: authorsâ€™ reply. <i>Pathology</i> , 2002, 34, 591.	0.3	6
789	A subcutaneous nodule: another variant of a pseudotumour? Part 1. <i>Pathology</i> , 2002, 34, 466-470.	0.3	0
790	Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. <i>Cancer</i> , 2002, 95, 671-672.	2.0	0
791	Hyalinising spindle cell tumour with giant rosettes: report of a case with unusual features including original histological and ultrastructural observations. <i>Pathology</i> , 2001, 33, 101-107.	0.3	5
792	Can phyllodes tumours of the breast be distinguished from fibroadenomas using fine needle aspiration cytology?. <i>Pathology</i> , 2001, 33, 437-443.	0.3	43

#	ARTICLE	IF	CITATIONS
793	Spinal chloroma presenting with triplegia in an aleukaemic patient. Pathology, 2001, 33, 386-389.	0.3	26
794	SPINAL CHLOROMA PRESENTING WITH TRIPLEGIA IN AN ALEUKAEMIC PATIENT. Pathology, 2001, 33, 386-389.	0.3	3
795	Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. Pathology, 2000, 32, 52-55.	0.3	6
796	Aggressive endometriosis: report of a case. International Journal of Gynecological Cancer, 2000, 10, 257-262.	1.2	13
797	Middle lobe syndrome due to obstructing solitary bronchial papilloma. Australian and New Zealand Journal of Medicine, 1999, 29, 745-747.	0.5	6
798	Hepatocellular carcinoma metastasizing to the orbit diagnosed by fine needle aspiration cytology. Pathology, 1999, 31, 350-353.	0.3	13
799	Test and Teach Number Ninety Six: Part 1. Pathology, 1999, 31, 372.	0.3	2
800	Test and teach Number Ninety-Four: Part 1. Pathology, 1999, 31, 217-218.	0.3	3
801	L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. Laboratory Investigation, 0, , .	1.7	5